Free Trial
→ GOP wipeout … but here's WORSE news for the market (From Weiss Ratings) (Ad)tc pixel Free TRUMY Stock Alerts

Terumo (TRUMY) Stock Forecast & Price Target

Terumo logo
$15.78 0.00 (0.00%)
As of 03:59 PM Eastern
Compare

Terumo - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Strong Buy
Based on 2 Analyst Ratings
Sell
0
Hold
0
Buy
2

Based on 2 Wall Street analysts who have issued ratings for Terumo in the last 12 months, the stock has a consensus rating of "Strong Buy." Out of the 2 analysts, 2 have given a strong buy rating for TRUMY.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for TRUMY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Terumo and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TRUMY Analyst Ratings Over Time

TypeCurrent Forecast
11/11/25 to 11/11/26		1 Month Ago
10/12/25 to 10/12/26		3 Months Ago
8/13/25 to 8/13/26		1 Year Ago
11/11/24 to 11/11/25
Strong Buy
2 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
 N/A
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
 N/A
Hold
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
 N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
 N/A
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingStrong BuyBuyBuyN/A

TRUMY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TRUMY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Terumo Stock vs. The Competition

TypeTerumoHealthcare CompaniesBroader Market
Consensus Rating Score
4.00
2.32
2.52
Consensus RatingStrong BuyHoldModerate Buy
Predicted UpsideN/A110.66% Upside13.61% Upside
News Sentiment Rating
Negative News

See Recent TRUMY News
Positive News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
10/13/2026
Zacks Research logo
Zacks Research
4 of 5 stars
 UpgradeHold ➝ Strong-Buy
7/30/2026
Nomura logo
Nomura
4 of 5 stars
 UpgradeHold ➝ Strong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:50 PM ET.


Should I Buy Terumo Stock? TRUMY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, November 5, 2026. Please send any questions or comments about these Terumo pros and cons to contact@marketbeat.com.

Terumo
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Terumo Co.:

  • Terumo Co. recently delivered a significant earnings surprise, reporting $0.30 in earnings per share for the quarter ended August 7, 2026, which exceeded the analyst consensus estimate of $0.17 by $0.13, demonstrating strong operational performance and profitability that can drive stock value.
  • The company has received a unanimous "Strong Buy" rating from major financial institutions, including upgrades from Nomura and Zacks Research in late 2026, signaling high institutional confidence in the stock's future growth potential and positive market sentiment.
  • Terumo Co. is trading at a current stock price of $16.43, which is near its 52-week high of $16.99, indicating strong upward momentum and investor demand that has pushed the share price significantly above its 52-week low of $12.08.
  • The company maintains a conservative balance sheet with a debt-to-equity ratio of 0.13, meaning it carries very little debt relative to its equity, which provides financial stability and reduces the risk of insolvency during economic downturns.
  • Terumo Co. operates in the essential healthcare sector with a diversified product portfolio including cardiovascular devices and blood management systems, providing a defensive investment profile that tends to be resilient against broader market volatility.

Terumo
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Terumo Co. for these reasons:

  • The stock is trading at a P/E ratio of 21.21, which is relatively high compared to many other healthcare companies, suggesting that the current price may already be fully valued or overvalued, leaving less room for price appreciation if earnings growth slows.
  • Terumo Co. offers a very low dividend yield of 0.37%, which may be insufficient to attract income-focused investors who seek regular cash flow from their investments, making the stock less appealing for those prioritizing yield over growth.
  • The company's beta of 0.82 indicates that while it is slightly less volatile than the overall market, it still carries market risk, and investors may face losses during broad market corrections despite its defensive sector positioning.
  • Short interest data shows fluctuations in short selling activity, with periods of increased short interest in mid-2026, suggesting that some market participants are betting against the stock's performance, which can create downward pressure on the share price.
  • The stock has experienced periods of high volatility and gap-down movements, such as the gap down observed in October 2026, indicating that the share price can be subject to sharp declines due to market sentiment shifts or broader economic concerns.

TRUMY Forecast - Frequently Asked Questions

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Terumo in the last year. There are currently 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "strong buy" TRUMY shares.

According to analysts, Terumo's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Terumo's stock had 1 upgrade by analysts.

Terumo has been rated by research analysts at Zacks Research in the past 90 days.

Analysts like Terumo more than other "healthcare" companies. The consensus rating for Terumo is Strong Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how TRUMY compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Terumo Recommendations


MarketBeat monitors more than a dozen sources for Terumo analyst ratings, with the most recent rating issued on 10/13/2026.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Don't lose access to this
Ian Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...
TradeWins | Sponsoredtc pixel